Reverse Item Response Theory Proposed for Sparsity-Robust Drug Sensitivity Ranking in Cancer Data
Researchers have introduced a reverse Item Response Theory framework to handle highly fragmented and sparse pharmacogenomic matrices. The method models cancer types as latent subjects and drugs as items, providing robust rankings even at high rates of missing data.
The research paper introduces reverse Item Response Theory to model cancer-type-level in-vitro resistance and drug-level broad activity on a shared latent scale. Applying this method to over two hundred thousand drug sensitivity measurements from the GDSC2 database, the model successfully treats cancer types as latent subjects with resistance ability and drugs as items with evasion difficulty. This reverse formulation addresses the persistent challenge of fragmented and incomplete datasets in pharmacogenomics.
Primary source
Open arXiv ↗This article summarizes the source. Check the original for full details and conditions.
Comparison
| Aspect | Before / Alternative | After / This |
|---|---|---|
| Evaluation modeling | Simple averaging of drug sensitivity metrics | Reverse Item Response Theory with latent variables for subjects and items |
| Sparsity robustness | Degraded ranking performance as missing data rates increase | Maintains ranking recovery with Delta-rho improvements of up to 0.095 at 60% missingness |
| Uncertainty quantification | Point estimates without reliable confidence bounds | Bootstrap confidence intervals confirming stability in 19 of 28 cancer classifications |
| Cross-platform generalizability | Assumed direct clinical extrapolation across different testing platforms | Robust methodological framework with high directional agreement but weak rank-order correlation |
